{"id":"W3087905898","doi":"10.1016/j.annonc.2020.08.2239","title":"LBA11 IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Puma Biotechnology; Syndax Pharmaceuticals; F. Hoffmann-La Roche; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Atezolizumab; Taxane; Internal medicine; Clinical endpoint; Anthracycline; Cyclophosphamide; Breast cancer; Oncology; Triple-negative breast cancer; Chemotherapy; Phases of clinical research; Placebo; Neoadjuvant therapy; Doxorubicin; Gastroenterology; Surgery; Cancer; Randomized controlled trial; Pathology; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001967897,0.001300876,0.001881964,0.000348648,0.0004149023,0.001376847,0.001190116,0.001169593,0.004324676],"category_scores_gemma":[0.001031171,0.0005437163,0.001719685,0.0004952904,0.0009297521,0.0008470204,0.0004720656,0.00423741,0.001372209],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001062781,"about_ca_system_score_gemma":0.001738141,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001867769,"about_ca_topic_score_gemma":0.008204713,"domain_scores_codex":[0.9995098,0.0002222586,0.0000232781,0.00007571422,0.00004950353,0.0001195013],"domain_scores_gemma":[0.9990653,0.0001773974,0.0001345194,0.00008642446,0.00005607658,0.0004802975],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5478737,0.0904021,0.01285554,0.001519624,0.003300073,0.000297845,0.0003550378,0.004279985,0.06093432,0.0005104124,0.01577745,0.261894],"study_design_scores_gemma":[0.3985244,0.543057,0.03287528,0.0001462369,0.002542264,0.0006993199,0.0001856412,0.002075631,0.007339687,0.0004650811,0.01200378,0.00008567038],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9799914,0.006522698,0.001033152,0.001667819,0.0003730094,0.001503297,0.00426604,0.0002574284,0.004385278],"genre_scores_gemma":[0.9646435,0.00666111,0.003609333,0.002903894,0.0003249531,0.002102223,0.01285106,0.0001737783,0.006730116],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004324676,"threshold_uncertainty_score":0.01446748,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.16364009510905,"score_gpt":0.4836415677196214,"score_spread":0.3200014726105714,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}